Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients with Psychogenic Nonepileptic Seizures (CRIPSY)

This open-label interventional trial (n=10) will evaluate the effect of a single 25 mg dose of psilocybin on neural correlates of cognitive control in patients with psychogenic non-epileptic seizures (PNES).

Conducted by the Centre Hospitalier Universitaire de Nîmes, this study aims to investigate whether psilocybin can enhance cognitive control in PNES patients by modulating brain activity in key executive control regions.

Participants will undergo MRI and fMRI scans before and after psilocybin administration to assess changes in blood-oxygen level-dependent (BOLD) signal fluctuations. The study will also examine the impact of psilocybin on emotional regulation, cognitive performance, seizure frequency, dissociative symptoms, and overall functional outcomes over a three-month period. Primary completion is estimated by May 2026, with full study completion expected in August 2026.

Topic Neuroscience
Compound Psilocybin
Country France
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.